06 October 2021 | Paul Dixey

Healthcare after the Pandemic

The world’s population is getting older. Today 1 in 11 are aged over 65 yet it is estimated this could rise to 1 in 6 by 2050. But is the healthcare system built to cope with this increasing level of demand? Our incredible doctors, nurses, scientists, and researchers have saved millions of lives over the last 18 months but what areas of the healthcare system need investment? How does one go about investing in the healthcare space, surrounded by risks such as drug pricing reform in the US, and the threat from the big technology companies?

In part two of this two-part episode, Paul Major Co-Manager of the BB Healthcare Trust - a £1bn FTSE250 listed investment trust - and I discuss these and other questions.



00:47 - Paul Major shares a couple of the healthcare sub segments that really excite him

08:18 - I ask him how he thinks about ESG issues when investing in healthcare

13:48 - President Biden has said on drug pricing, “there aren’t a lot of things that almost every American could agree on, but I think it is safe to say that all of us, whatever our background, or our age and where we live, could agree that prescription drug prices are outrageously expensive in America” I ask Paul where we are in the reform process and how he manages this risk

22:17 - Another threat to the healthcare sector comes in the form of the Big Tech companies, we discuss the role they will play in the sector from now on

26:50 - During the pandemic telemedicine unsurprisingly experienced huge demand, but as we emerge from the pandemic does it have a future

31:30 - Stock markets have had a great run from the lows of last year and we discuss why the healthcare sector is deemed a defensive one and if now is the time to be increasing our exposure


Back to News & Insights

Terms & Conditions

The information and services described on this website are not intended to be used by, or to be available to, persons accessing the website from outside the United Kingdom.

The value of investments and the income derived from them may go down as well as up and you may not receive back all the money which you invest.

The investments and investment services described or recommended on this website may not be suitable for all people.

Any information relating to past performance of an investment or investment service is not a reliable indicator of future performance.

No tax advice is provided and clients will need to seek advice from their independent tax advisor.

Fluctuations in the rate of exchange may have an adverse effect on the value, price or income of non-sterling denominated investments.

Vermeer Investment Management Limited, its associates, employees and/or clients may own or have a position in securities referred to on this website or may have provided advice or investment services in relation to any such security.

The Website is for information purposes only. Information contained on it is not intended to be an offer to buy or sell securities and this website should not be regarded as an offer or solicitation to conduct investment business as defined in section 21 of the UK Financial Services and Markets Act 2000 (FSMA).

Nothing on this website is intended to exclude or restrict any duty or liability which Vermeer Investment Management Limited may have under the FSMA (or any subsequent amending or replacement legislation) or the rules and regulations for the conduct of business made thereunder.

For the purposes of FSMA this website has been approved by Vermeer Investment Management Limited, which is authorized & regulated by the Financial Conduct Authority.

Please read our Privacy Policy. By clicking ‘accept’ you agree to be bound by the terms of this notice.